



ELMMB Formulary Update

June 2019

Subscribe Now

And be one of the first to know...

BLACK traffic Light - not recommended for prescribing in primary or secondary care.

- **Dabrafenib with trametinib** – advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer – appraisal terminated - [NICE TA564](#)
- **Abatacept** – psoriatic arthritis after DMARDs – appraisal terminated – [NICE TA568](#)
- **Pembrolizumab** - recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy – appraisal terminated – [NICE TA570](#)
- **Bosutinib** – untreated chronic myeloid leukaemia – appraisal terminated – [NICE TA576](#)
- **Bevacizumab with carboplatin, gemcitabine and paclitaxel** – platinum- sensitive advanced ovarian cancer – appraisal terminated - [NICE TA560](#)
- **Fortacin** [Lidocaine/Prilocaine Spray] – Primary premature ejaculation in adult men
- **Ospemifene** – vulvar & vaginal atrophy in post-menopausal women

RED traffic light - Primary care prescribers should not be asked to prescribe (** denotes NHS England Commissioned)

- **Abemaciclib with an aromatase inhibitor**** – previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer – an option in [NICE TA563](#)
- **Benralizumab**** – severe eosinophilic asthma – an option in [NICE TA565](#)
- **Brigatinib** – ALK-positive advanced non-small-cell lung cancer after crizotinib – an option in [NICE TA571](#)
- **Brentuximab vedotin**** – CD30-positive cutaneous T-cell lymphoma – an option in [NICE TA577](#)
- **Venetoclax with rituximab** - previously treated chronic lymphocytic leukaemia – an option in [NICE TA561](#) (Cancer Drugs Fund)
- **Visu-XI®** - slow epithelial healing, specialist use only.
- **Pertuzumab** – adjuvant treatment of HER2-positive early stage breast cancer – an option in [NICE TA569](#)
- **Certolizumab pegol** – moderate to severe plaque psoriasis – an option in [NICE TA574](#) [Blueteq form req'd]
- **VSL~3 Sachets** – for specialist gastroenterology use only
- **Encorafenib with binimetinib** unresectable or metastatic BRAF V600 mutation-positive melanoma – an option in [NICE TA562](#) (Cancer Drugs Fund)
- **Alicaforsen Enema** – refractory puchitis – for use by Consultant Gastroenterologist only.
- **Tisagenlecleucel** – relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies – an option in [NICE TA567](#)(Cancer Drugs Fund)
- **Tildrakizumab** – moderate to severe plaque psoriasis – an option in [NICE TA575](#) [Blueteq form req'd]
- **Daratumumab with bortezomib and dexamethasone** - previously treated multiple myeloma - an option in [NICE TA573](#)(Cancer Drugs Fund)

AMBER Traffic Light - initiated by specialists but may then be passed to primary care for prescribing

- **Tranexamic acid injection** – topical use when recommended by specialist palliative care services
- **Systane Balance®** - evaporative dry eye, specialist initiation only

GREEN Traffic Light - may be prescribed by all prescribers within local or national recommendations

- **Diltiazem MR capsules** – ELHT switching brand to **Viazem®**
- **Ertugliflozin**- as monotherapy or with metformin for treating Type 2 diabetes – an option in [NICE TA572](#)

Prescribing
Hot Topic

Formulary
Updates

Drug Safety
Updates



East Lancashire Health Economy
Medicines Management Board

www.elmmb.nhs.uk 

ELMMB Formulary Update

June 2019... continued

Subscribe Now

And be one of the first to know...

Guidelines

- [Denosumab Shared Care Guideline](#) – updated to include treatment of induced osteoporosis
- [Antihistamines Prescribing Policy](#) – accepted for use by ELMMB
- [UTI Assessment Form for Care Homes](#) – acknowledged by ELMMB
- [Nebulised Colomycin® in Non-CF Bronchiectasis Prescribing Sheet](#) – updated
- [ELCCG/ELHT Wound Care Formulary](#) Updated
- [Trans-anal Irrigation Systems Position Statement](#) - updated
- [Low Molecular Weight Heparin Guidelines](#) – updated to include enoxaparin for prophylaxis due to supply issues
- [Guidance for Prescribing Second Generation Long Acting Anti-psychotic injections \[LCFT\]](#)
- [Waterproof Cast Covers](#) – Position Statement

Other

- [Medicines Management Board Minutes](#)
- [MHRA Drug Safety Updates](#)
- [Drug Safety Updates](#)
- [Prescribing Hot Topics](#)
- [Nice Bites](#)
- [NICE Visual Summaries](#)

The Joint Medicines Formulary is applicable to ALL prescribers in both primary and secondary care across the East Lancashire Health Economy

Please note that items **not listed** in the Joint Medicines Formulary are deemed unsuitable to prescribe.

The ELHE joint formulary has been designed to make it both useful and effective.

The main features are:

- it is a constantly evolving and dynamic document providing guidance on appropriate and cost effective prescribing
- it contains some prescribing notes with key messages on best practice
- it aims to ensure that patients have continuity of medicines across the interface between primary care and secondary care
- it aims to help prescribers choose the most appropriate medicines whilst ensuring value for money in the use of NHS resources

Key to symbols used throughout the Joint Medicines Formulary

GREEN Medicines which may be freely prescribed by all prescribers within local or national recommendations.

AMBER Medicines which should only be initiated/recommended by specialists but which may then be passed to primary care prescribers for prescribing

AMBER WITH SHARED CARE These are still AMBER medicines which should only be initiated in secondary care but which may be passed to primary care prescribers for prescribing provided the terms of a locally agreed shared care protocol (where available) are met.

RED Medicines which should only be used within the secondary care setting. Primary care prescribers should not be asked to prescribe.

BLACK These are medicines that have been reviewed and have been deemed less suitable for prescribing, and are therefore not recommended in primary or secondary care. This may be due to the lack of good clinical evidence, or due to the availability of more suitable alternatives.

'Follow' us on  or 'Like' us on 

Email info.elmmb@nhs.net with any comments or questions